Jeeshan Chowdhury Headshot
Report a problem with this profile
[email protected]

Jeeshan Chowdhury    

Founder & CEO of Journey Colab; Entrepreneur; Trained in Psychedelic-Assisted Therapy

Jeeshan Chowdhury is Founder & CEO of Journey Colab, part of Sam Altman’s inaugural cohort of Apollo Projects Fund. Journey Colab is taking a portfolio of plant inspired psychedelic compounds through FDA for therapeutic use, beginning with mescaline, and seeks to transform mental health care by scaling a company that benefits all stakeholders.

He is is an MD/DPhil and studied at Oxford as a Rhodes Scholar. He launched his first company through YCombinator and is enrolled in the 2020 CIIS CPTR program.


Mental Health Startup Journey Colab Aims To Develop Mescaline As An FDA-Approved Treatment For Alcohol Use Disorder
Journey Colab, a California biopharma startup, leads the effort to develop an FDA-approved form of mescaline, a psychoactive molecule that occurs naturally in peyote, as a therapeutic to assist with the treatment of AUD. Cognizant of the traditional discoverers of this potential therapeutic, this company, in an arrangement that is to my knowledge unique among biopharma startups, set aside a 10% equity stake to benefit traditional peyote stewards and the AUD treatment communities. I spoke with Journey Colab’s founder and CEO, Jeeshan Chowdhury, its acting COO and CLO, Rebecca Lee, indigenous rights activist, impact advisor and trustee Sutton King, and addiction expert and recently-appointed scientific advisor Kelly J. Clark about the company’s goals, genesis, and unique structure.

Related Speakers View all

More like Jeeshan